Phase I Study of MEK162 for Children with Progressive or Recurrent Cancer and a Phase II Study of Children with Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors

Grant

Date/time Interval

  • May 30, 2017 - May 29, 2018
  • Total Award Amount

  • 0.00
  • Direct Costs

  • 0.00
  • Sponsor Award Id

  • Contributor

  • Elizabeth Alva   Investigator  
  • Gregory Friedman M.D.   Investigator